Treatment of stage III carcinoma ovary: March 2013
**Question:** Treatment of stage III carcinoma ovary: March 2013
**Core Concept:** Treatment of advanced ovarian cancer involves a combination of surgical debulking and systemic chemotherapy, aiming to achieve optimal cytoreduction and improve patient outcomes.
**Why the Correct Answer is Right:**
Correct Answer: C (Cyclophosphamide, Mitomycin C, and Paclitaxel)
In the context of stage III carcinoma ovary, a treatment approach typically involves a combination of surgical debulking and systemic chemotherapy. The correct answer, C (Cyclophosphamide, Mitomycin C, and Paclitaxel), is part of the standard first-line chemotherapy regimen for advanced ovarian cancer, specifically for patients with optimal debulking surgery (no visible residual disease).
**Why Each Wrong Option is Incorrect:**
A. Optimal debulking surgery alone is insufficient for treating stage III carcinoma ovary, as it does not address the systemic spread of the disease.
B. Systemic chemotherapy with monotherapy agents like Carboplatin or Cisplatin is less effective compared to combination therapy.
D. Combination therapy with different drugs like Adriamycin and Cisplatin is not the standard treatment for stage III carcinoma ovary, as it is considered outdated and less effective compared to the chosen regimen (Cyclophosphamide, Mitomycin C, and Paclitaxel).
**Why Each Wrong Option is Incorrect:**
A. Optimal debulking surgery alone is insufficient for treating stage III carcinoma ovary, as it does not address the systemic spread of the disease.
B. Systemic chemotherapy with monotherapy agents like Carboplatin or Cisplatin is less effective compared to combination therapy.
D. Combination therapy with different drugs like Adriamycin and Cisplatin is not the standard treatment for stage III carcinoma ovary, as it is considered outdated and less effective compared to the chosen regimen (Cyclophosphamide, Mitomycin C, and Paclitaxel).
**Clinical Pearls:**
The optimal treatment for stage III carcinoma ovary involves a combination of cytoreductive surgery (to minimize the amount of residual disease) and systemic chemotherapy using Cyclophosphamide, Mitomycin C, and Paclitaxel. This combination regimen is known to achieve better overall response rates, progression-free survival, and overall survival compared to single-agent chemotherapy or other regimens.
Additionally, the choice of drugs in this regimen (Cyclophosphamide, Mitomycin C, and Paclitaxel) targets different aspects of cancer cell growth and survival, increasing the efficacy of the therapy.
Cyclophosphamide is a cytotoxic agent that inhibits DNA synthesis and repair, causing cell death in rapidly dividing cells, including cancer cells.
Mitomycin C is a cross-linking agent that interferes with DNA replication and repair, leading to cell cycle arrest and apoptosis.
Paclitaxel is a microtubule inhibitor that stabilizes microtubules, preventing the depolymerization of tubulin and inducing cell cycle arrest and apoptosis in cancer cells.
The combination of these drugs allows for a synergistic effect